194 related articles for article (PubMed ID: 23842041)
21. Hepatocellular Carcinoma: In Vivo Evaluation of Water Percentage as a Prognostic Biomarker Using Magnetic Resonance Imaging 3D-VIBE Multiecho Dixon.
Wang M; Yuan F; Wei Y; Xia C; Hu F; Song B
Cancer Biother Radiopharm; 2018 Sep; 33(7):300-306. PubMed ID: 30109954
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
23. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
24. Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?
Suh JY; Cho G; Song Y; Lee CK; Kang JS; Kang MR; Park SB; Kim YR; Kim JK
J Magn Reson Imaging; 2012 Jun; 35(6):1430-6. PubMed ID: 22314928
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB; Cohen EI; Ocean A; Lehrer D; Goldenberg A; Knox JJ; Chen H; Clark-Garvey S; Weinberg A; Mandeli J; Christos P; Mazumdar M; Popa E; Brown RS; Rafii S; Schwartz JD
J Clin Oncol; 2008 Jun; 26(18):2992-8. PubMed ID: 18565886
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.
Mauge L; Mejean A; Fournier L; Pereira H; Etienne-Grimaldi MC; Levionnois E; Caty A; Abadie-Lacourtoisie S; Culine S; Le Moulec S; Linassier C; Théodore C; Ravaud A; Albiges L; Grine A; Tartour E; Milano G; Gille AS; Verkarre V; Helley D; Oudard S;
Clin Cancer Res; 2018 Nov; 24(22):5534-5542. PubMed ID: 30061359
[No Abstract] [Full Text] [Related]
27. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
28. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.
Chung C; Jalali S; Foltz W; Burrell K; Wildgoose P; Lindsay P; Graves C; Camphausen K; Milosevic M; Jaffray D; Zadeh G; Ménard C
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):805-12. PubMed ID: 22929856
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Chen X; Ma Z; Huang Y; He L; Liang C; Shi C; Zhang Z; Liang C; Liu Z
J Magn Reson Imaging; 2017 Jul; 46(1):248-256. PubMed ID: 27783444
[TBL] [Abstract][Full Text] [Related]
32. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
33. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
34. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386
[TBL] [Abstract][Full Text] [Related]
35. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
[TBL] [Abstract][Full Text] [Related]
37. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative diffusion-weighted imaging?
Xu P; Zeng M; Liu K; Shan Y; Xu C; Lin J
J Gastroenterol Hepatol; 2014 Feb; 29(2):330-6. PubMed ID: 24033853
[TBL] [Abstract][Full Text] [Related]
38. ADC
Wu L; Xu P; Rao S; Yang L; Chen C; Liu H; Fu C; Zeng M
J Magn Reson Imaging; 2017 Sep; 46(3):820-830. PubMed ID: 28276105
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
